PAXIP1 and central nervous system cancer: Overall survival was significantly longer in the low expression group for lncRNAs PAXIP1-AS2, RP11-303E16.2, RP11-157J24.2, RP11-108L7.15, while with lncRNAs AC091878.1, LNC00632, RP11-158M2.3, and CTD-2377O17.1 the overall survival was significantly longer in the high expression group, indicating their protective roles in glioma.